AU2009231511B2 - In vitro diagnostic method for the diagnosis of somatic and ovarian cancers - Google Patents
In vitro diagnostic method for the diagnosis of somatic and ovarian cancers Download PDFInfo
- Publication number
- AU2009231511B2 AU2009231511B2 AU2009231511A AU2009231511A AU2009231511B2 AU 2009231511 B2 AU2009231511 B2 AU 2009231511B2 AU 2009231511 A AU2009231511 A AU 2009231511A AU 2009231511 A AU2009231511 A AU 2009231511A AU 2009231511 B2 AU2009231511 B2 AU 2009231511B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- nucleic acid
- acid molecules
- proteins
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000392 somatic effect Effects 0.000 title claims description 148
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims description 76
- 238000003745 diagnosis Methods 0.000 title claims description 59
- 238000000338 in vitro Methods 0.000 title claims description 51
- 238000002405 diagnostic procedure Methods 0.000 title description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 539
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 414
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 414
- 239000012634 fragment Substances 0.000 claims abstract description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 732
- 102000004169 proteins and genes Human genes 0.000 claims description 267
- 206010028980 Neoplasm Diseases 0.000 claims description 259
- 201000011510 cancer Diseases 0.000 claims description 184
- 150000001413 amino acids Chemical class 0.000 claims description 135
- 239000000523 sample Substances 0.000 claims description 118
- 238000000034 method Methods 0.000 claims description 62
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 61
- 239000002751 oligonucleotide probe Substances 0.000 claims description 61
- 239000012472 biological sample Substances 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 238000002493 microarray Methods 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 39
- 108091034117 Oligonucleotide Proteins 0.000 claims description 39
- 206010033128 Ovarian cancer Diseases 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 230000002159 abnormal effect Effects 0.000 claims description 18
- 238000012408 PCR amplification Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000013642 negative control Substances 0.000 claims description 13
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- 238000003365 immunocytochemistry Methods 0.000 claims description 7
- 238000010166 immunofluorescence Methods 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 7
- 238000001114 immunoprecipitation Methods 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000013641 positive control Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 108020004635 Complementary DNA Proteins 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 230000000052 comparative effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 197
- 210000001550 testis Anatomy 0.000 description 161
- 230000014509 gene expression Effects 0.000 description 154
- 210000002826 placenta Anatomy 0.000 description 129
- 210000001519 tissue Anatomy 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 78
- 235000001014 amino acid Nutrition 0.000 description 69
- 230000000875 corresponding effect Effects 0.000 description 48
- 241000282414 Homo sapiens Species 0.000 description 38
- 230000001973 epigenetic effect Effects 0.000 description 32
- 238000013459 approach Methods 0.000 description 25
- 210000001082 somatic cell Anatomy 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 238000009396 hybridization Methods 0.000 description 18
- 210000004602 germ cell Anatomy 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 16
- 230000002074 deregulated effect Effects 0.000 description 14
- 230000001594 aberrant effect Effects 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000003211 malignant effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010033040 Histones Proteins 0.000 description 11
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 11
- 230000003831 deregulation Effects 0.000 description 11
- 230000009368 gene silencing by RNA Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 230000007067 DNA methylation Effects 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 230000011987 methylation Effects 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000000126 in silico method Methods 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 102000006947 Histones Human genes 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 101150070926 ct gene Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000010307 cell transformation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000010197 meta-analysis Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000002980 germ line cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- -1 rRNA Proteins 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 210000002863 seminiferous tubule Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013075 data extraction Methods 0.000 description 2
- 238000007418 data mining Methods 0.000 description 2
- 238000013079 data visualisation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000006543 gametophyte development Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 239000010754 BS 2869 Class F Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 101150033052 MAS5 gene Proteins 0.000 description 1
- 206010025598 Malignant hydatidiform mole Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- UIQWBVPFHHQZHH-UHFFFAOYSA-N OOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOO UIQWBVPFHHQZHH-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002937 blood-testis barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 201000008814 placenta cancer Diseases 0.000 description 1
- 201000008824 placental choriocarcinoma Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290307.1 | 2008-03-31 | ||
| EP20080290307 EP2107127A1 (en) | 2008-03-31 | 2008-03-31 | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers |
| PCT/EP2009/053809 WO2009121878A2 (en) | 2008-03-31 | 2009-03-31 | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009231511A1 AU2009231511A1 (en) | 2009-10-08 |
| AU2009231511B2 true AU2009231511B2 (en) | 2014-07-03 |
Family
ID=39789414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009231511A Ceased AU2009231511B2 (en) | 2008-03-31 | 2009-03-31 | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110059856A1 (https=) |
| EP (2) | EP2107127A1 (https=) |
| JP (1) | JP2011517937A (https=) |
| AU (1) | AU2009231511B2 (https=) |
| WO (1) | WO2009121878A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542573A1 (en) | 2010-03-02 | 2013-01-09 | Technische Universität Dresden | Novel protein with structural homology to proteins with il-8-like chemokine fold and uses thereof |
| EP2444504A1 (en) * | 2010-10-20 | 2012-04-25 | Université Joseph Fourier | Use of specific genes or their encoded proteins for a prognosis method of classified lung cancer |
| EP2444503B1 (en) * | 2010-10-20 | 2016-03-02 | Université Joseph Fourier | Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method |
| US9568486B2 (en) * | 2011-02-15 | 2017-02-14 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of ectopic pregnancy |
| EP2620772A1 (en) * | 2012-01-25 | 2013-07-31 | APP Latvijas Biomedicinas petijumu un studiju centrs | Gastric cancer biomarkers and methods of use thereof |
| US9903870B2 (en) | 2012-10-04 | 2018-02-27 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for the diagnosis of ovarian cancer |
| US10745761B2 (en) | 2014-06-02 | 2020-08-18 | Valley Health System | Method and systems for lung cancer diagnosis |
| US20220177891A1 (en) * | 2019-02-19 | 2022-06-09 | Board Of Regents, The University Of Texas System | Hipk inhibitors and methods of use thereof |
| CN110577991B (zh) * | 2019-09-23 | 2022-05-27 | 中国人民解放军陆军军医大学 | 一种用于非阻塞性无精症的诊断盒 |
| JP2024501482A (ja) * | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029176A2 (en) * | 2004-09-08 | 2006-03-16 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4503801B2 (ja) * | 2000-09-08 | 2010-07-14 | 独立行政法人科学技術振興機構 | 新規ヒト癌・精巣抗原及びその遺伝子 |
| EP1308459A3 (en) * | 2001-11-05 | 2003-07-09 | Research Association for Biotechnology | Full-length cDNA sequences |
| EP1938104A2 (en) * | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070128636A1 (en) * | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| EP1795596A1 (en) * | 2005-12-08 | 2007-06-13 | Ganymed Pharmaceuticals AG | Composition and methods for therapy and diagnosis of cancer |
| CA2643225A1 (en) * | 2006-02-28 | 2007-09-07 | Pfizer Products Inc. | Gene predictors of response to metastatic colorectal chemotherapy |
| US20100009905A1 (en) * | 2006-03-24 | 2010-01-14 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer |
| WO2008103645A2 (en) * | 2007-02-19 | 2008-08-28 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
-
2008
- 2008-03-31 EP EP20080290307 patent/EP2107127A1/en not_active Withdrawn
-
2009
- 2009-03-31 JP JP2011502373A patent/JP2011517937A/ja active Pending
- 2009-03-31 AU AU2009231511A patent/AU2009231511B2/en not_active Ceased
- 2009-03-31 WO PCT/EP2009/053809 patent/WO2009121878A2/en not_active Ceased
- 2009-03-31 EP EP09726587.0A patent/EP2640845B1/en not_active Not-in-force
- 2009-03-31 US US12/935,768 patent/US20110059856A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029176A2 (en) * | 2004-09-08 | 2006-03-16 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
Non-Patent Citations (2)
| Title |
|---|
| CONDOMINES, M. et al. Blood 2007, vol. 110, abs. 1793 * |
| YOKOE, T. et al., Cancer Res. 2008, vol. 68, pp 1074-1082 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009121878A3 (en) | 2010-01-21 |
| JP2011517937A (ja) | 2011-06-23 |
| US20110059856A1 (en) | 2011-03-10 |
| WO2009121878A2 (en) | 2009-10-08 |
| EP2640845A2 (en) | 2013-09-25 |
| EP2640845B1 (en) | 2017-09-13 |
| EP2107127A1 (en) | 2009-10-07 |
| AU2009231511A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009231511B2 (en) | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers | |
| US20220145390A1 (en) | Assay for determining the type and/or status of a cell based on the epigenetic pattern and the chromatin structure | |
| US11384397B2 (en) | Methods and compositions for diagnosing, prognosing, and treating endometriosis | |
| EP3071708B1 (en) | Methods for the surveillance, diagnosis and screening of bladder cancer | |
| US20160168649A1 (en) | Gene expression predictors of cancer prognosis | |
| US9976187B2 (en) | Methylation biomarkers for prostate cancer | |
| KR20150100698A (ko) | 갑상선 종양을 진단하기 위한 조성물 및 방법 | |
| JP2003530091A (ja) | ミトコンドリア線量計 | |
| US20210395834A1 (en) | Abca1 downregulation in prostate cancer | |
| US20070196843A1 (en) | Method for identification and monitoring of epigenetic modifications | |
| Song et al. | Single-cell multiomics reveals ENL mutation perturbs kidney developmental trajectory by rewiring gene regulatory landscape | |
| JP2010509926A (ja) | 前立腺細胞増殖性障害の発症に関連する遺伝子の発現を解析する方法及び核酸 | |
| JP6949315B2 (ja) | 肺扁平上皮癌と肺腺癌の鑑別評価方法 | |
| WO2015105190A1 (ja) | 子宮体がんのリンパ節転移能の評価方法 | |
| US11118212B2 (en) | Methods for detecting rapidly processed introns to evaluate allelic expression | |
| WO2015105191A1 (ja) | リンパ節腫脹病変の評価方法 | |
| Du et al. | A simple oligonucleotide biochip capable of rapidly detecting known mitochondrial DNA mutations in Chinese patients with Leber’s hereditary optic neuropathy (LHON) | |
| HK40005244A (en) | Methods and compositions for diagnosing, prognosing, and treating endometriosis | |
| CA2876115A1 (en) | Methylation biomarkers for prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: UNIVERSITE GRENOBLE ALPES Free format text: FORMER OWNER(S): UNIVERSITE JOSEPH FOURIER; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Free format text: FORMER OWNER(S): UNIVERSITE JOSEPH FOURIER; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |